Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bal Pharma Launches Antiviral Drug Favipiravir at Rs 85/Tablet
Details : Balflu (favipiravir) is a RNA-directed RNA polymerase inhibitor, which is approved for the treatment of patients with mild to moderate Covid-19 Infection.
Product Name : Balflu
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2021
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable